WebMD Health Corp (WBMD) - NASDAQ
  • Fri, Jun. 10, 7:28 AM
    • Sarepta Therapeutics (NASDAQ:SRPT) upgraded to Outperform from Neutral by Wedbush. Price target raised to $36 (71% upside) from $14.
    • EnteroMedics (NASDAQ:ETRM) downgraded to Neutral from Buy by Roth Capital Partners. Price target is $0.50 (11% upside).
    • Relypsa (NASDAQ:RLYP) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target maintained at $9 (52% downside risk).
    • Mirati Therapeutics (NASDAQ:MRTX) downgraded to Hold from Buy by Jefferies. Price target lowered to $17 (77% upside) from $27.
    • AbbVie (NYSE:ABBV) downgraded to Market Perform from Outperform by Cowen & Company. Price target lowered to $70 (15% upside) from $77. Downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $65 (7% upside) from $73.
    • WebMD (NASDAQ:WBMD) downgraded to Market Perform from Outperform by William Blair.
    | Fri, Jun. 10, 7:28 AM | 9 Comments
  • Thu, May 26, 1:13 PM
    • WebMD (WBMD -5.9%) is selling $300M worth of convertible notes due 2023. The notes carry a 2.625% interest rate, and a conversion price of $87.07 (38% above current levels).
    • Net proceeds will be used for "general corporate purposes, which may include acquisitions, repurchases of WebMD common stock, repurchases of outstanding convertible notes and for working capital." WebMD had $593M in cash and $700M in convertible debt at the end of Q1. $397M worth of convertible notes were due in 2018, and $295M due in 2020.
    | Thu, May 26, 1:13 PM
  • Wed, May 25, 5:39 PM
    | Wed, May 25, 5:39 PM
  • Fri, May 13, 11:35 AM
    • Prothena (PRTA +7.6%) initiated with Overweight rating and $60 (44% upside) price target by Barclays.
    • Pfizer (PFE +0.5%) initiated with Hold rating and $38 (12% upside) price target by Berenberg.
    • Amarin (AMRN +1.9%) initiated with Buy rating and $3.50 (111% upside) price target by Jefferies.
    • Align Technology (ALGN +0.9%) initiated with Outperform rating and $84 (10% upside) price target by Credit Suisse.
    • Presbia (LENS +2.9%) initiated with Buy rating and $14 (254% upside) price target by Rodman & Renshaw.
    • LabStyle Innovations (OTCQB:DRIO +5.4%) initiated with Buy rating and $12 (121% upside) price target by Rodman & Renshaw.
    • Juno Therapeutics (JUNO +1.5%) initiated with an Outperform rating and $55 (48% upside) price target by Cowen & Co.
    • WebMD Health (WBMD +0.4%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target increased to $75 (18% upside) from $57.
    • Sanofi (SNY +0.3%) upgraded to Overweight from Equal Weight by Barclays. Price target maintained at €84 (20% upside).
    • Depomed (DEPO +4.1%) upgraded to Buy from Neutral by Mizuho Securities. Price target raised to $19 (4% upside) from $18.
    | Fri, May 13, 11:35 AM
  • Wed, May 4, 4:16 PM
    • WebMD Health Corp (NASDAQ:WBMD): Q1 EPS of $0.36 beats by $0.03.
    • Revenue of $158.6M (+10.7% Y/Y) beats by $1.99M.
    • Press Release
    | Wed, May 4, 4:16 PM
  • Tue, May 3, 5:35 PM
  • Wed, Mar. 30, 5:39 PM
    • Top gainers, as of 5.25 p.m.: MDVN +13.9%. VALE +13.4%. EPE +12.0%. AU +4.6%. WBMD +3.5%.
    • Top losers, as of 5.25p.m.: PRGS -10.6%. VRNT -6.6%. SLW -5.9%. OHI -1.6%. MAS -1.5%.
    | Wed, Mar. 30, 5:39 PM
  • Thu, Mar. 24, 4:05 PM
    • Accelerate Diagnostics (AXDX +12.7%) initiated with Overweight rating and $17 (26% upside) price target by JP Morgan.
    • Inogen (INGN -2.1%) initiated with Neutral rating with a $46 (15% upside) price target by Piper Jaffray.
    • Incyte (INCY +3.3%) initiated with Overweight rating and $85 (21% upside) price target by Morgan Stanley.
    • West Pharmaceutical Services (WST -0.1%) initiated with Outperform rating with a $69 (6% upside) price target by Wells Fargo.
    • Ironwood Pharmaceuticals (IRWD +1%) initiated with Neutral rating and $14 (35% upside) price target by Goldman Sachs.
    • HeartWare International (HTWR -0.4%) upgraded to Buy from Neutral by Bank of America.
    • WebMD (WBMD +0.4%) upgraded to 3.5 stars from 3.0 stars (out of 5.0) by top raters at Vetr community. Price target is $62.50 (7% upside).
    • Tandem Diabetes (TNDM -15.7%) downgraded to Underperform from Neutral by Bank of America.
    • EndoChoice (GI -9.1%) downgraded to Underperform from Buy with a $10 price target by Bank of America.
    • DENTSPLY (XRAY -1.6%) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target is $65 (9% upside).
    • Novartis (NVS -0.8%) downgraded to Market Perform from Outperform by Leerink. Price target lowered to $85 (16% upside) from $98.
    • Infinity Pharmaceuticals (INFI -4.3%) downgraded to Underperform from Neutral by Wedbush. Price target lowered to $3 (40% downside risk) from $8.
    • Valeant Pharmaceuticals (VRX -7%) downgraded to Equal Weight with $34 (10% upside) price target by Barclays. Downgraded to Underperform from Neutral by Mizuho. Price target lowered to $18 (42% downside risk) from $70.
    | Thu, Mar. 24, 4:05 PM | 7 Comments
  • Tue, Feb. 23, 5:30 PM
    • WebMD's (NASDAQ:WBMD) Q4 beat has been accompanied by guidance for Q1 revenue of $154.5M-$157.5M (+8%-10% Y/Y) and 2016 revenue of $685M-$705M (+8%-11%), favorable at the midpoints to consensus estimates of $154.6M and $689.9M. In addition, 2016 EPS guidance of $1.75-$1.90 (compares with 2015 EPS of $1.48) is above a $1.66 consensus.
    • Top-line performance/metrics: Ad/sponsorship revenue rose 25% Y/Y in Q4 to $$158.3M. Private portal services revenue fell 5% to $27.2M, and information services revenue 7% to $6.6M. Traffic rose 6% Y/Y to 3.97B page views; monthly unique users rose 7% to 201M.
    • Financials: Cost controls lifted EPS: G&A spend fell by $600K Y/Y to $24.2M. Sales/marketing spend rose by $3.1M to $40.1M. $34M was spent on buybacks. WebMD ended 2015 with $641M in cash and $803M in convertible debt.
    • WBMD +4% after hours to $54.00 The 52-week high is $58.25.
    • WebMD's Q4 results, earnings release
    | Tue, Feb. 23, 5:30 PM
  • Tue, Feb. 23, 4:05 PM
    • WebMD Health Corp (NASDAQ:WBMD): Q4 EPS of $0.60 beats by $0.03.
    • Revenue of $192.1M (+18.0% Y/Y) beats by $2.17M.
    • Shares +3.5%.
    • Press Release
    | Tue, Feb. 23, 4:05 PM
  • Mon, Feb. 22, 5:35 PM
  • Thu, Feb. 11, 3:45 PM
    • U.K. finance blogger Betaville reports hearing i-bank Moelis is "trying to broker a deal" between WebMD (WBMD +4.5%) and drugstore giant Walgreens Boots. Walgreen is said to have "already submitted an indicative offer."
    • The FT reported in January WebMD is exploring a sale of all or part of its business. However, soon afterwards, the company stated it's "not currently in any negotiations to be acquired."
    • Q4 results arrive on the afternoon of Feb. 23.
    | Thu, Feb. 11, 3:45 PM | 1 Comment
  • Mon, Feb. 1, 5:37 PM
    | Mon, Feb. 1, 5:37 PM
  • Thu, Jan. 14, 10:59 AM
    • In response to an overnight FT report stating the company is thinking of partly or fully selling itself, WebMD (NASDAQ:WBMD) states it's "not currently in any negotiations to be acquired."
    • Shares have given back their early gains, and then some. They rose yesterday (in spite of a steep market selloff) after WebMD favorably revised its Q4 guidance and offered an initial 2016 sales outlook.
    | Thu, Jan. 14, 10:59 AM
  • Thu, Jan. 14, 9:16 AM
    | Thu, Jan. 14, 9:16 AM
  • Thu, Jan. 14, 2:51 AM
    • WebMD (NASDAQ:WBMD), the U.S. online health information publisher, is exploring the possible sale of all or part of its business, FT reports.
    • The company is said to be in talks with Walgreens Boots Alliance (NASDAQ:WBA) and UnitedHealth (NYSE:UNH), among other potential buyers.
    • Since the start of the year WebMD shares have risen 10%, giving the company a market value of close to $2B.
    • Update: Shares are up 6% premarket on increased volume.
    | Thu, Jan. 14, 2:51 AM
Company Description
WebMD Health Corp. provides health information services to consumers, physicians and other healthcare professionals, employers and health plans through its public and private online portals, mobile platforms and health-focused publications. Its online healthcare information, decision-support... More
Sector: Technology
Industry: Internet Information Providers
Country: United States